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Context: Understanding how hospital outcomes for common conditions differ for white
and black patients will help to determine better targets for interventions to ameliorate
disparities.
Background
Contrary to observations from many other settings, black patients in VA hospitals have
been shown to have better 30-day mortality outcomes than white patients. Because these
results surprised many, Volpp and Polsky et al used VA data to confirm this mortality
advantage for six Agency for Healthcare Research and Quality (AHRQ) hospital quality
indicators: heart attack (AMI), stroke, hip fracture, congestive heart failure (CHF),
gastrointestinal bleeding (GI bleed) and pneumonia. They also eliminated VA hospital
site, co-morbid conditions, and changing mortality rates over time as potential sources of
the observed outcome differences between white and black veteran patients. In addition,
the investigators negated the idea that population characteristics among those who are
treated in VA hospitals, such as younger age of black veterans or higher socioeconomic
status of white veterans, explains differences in mortality by race. They did find that the
survival advantage among black veterans being treated in VA hospitals for the six
conditions applied only to those over age 65; among younger veterans, black patients
had lower mortality rates only for CHF.
This issue of the CHERP Policy Brief focuses on a subsequent project in which the
investigators extended their research in two ways: 1) they looked beyond the VA health
care system for evidence of similarly patterned racial differences in mortality for the six
conditions and 2) they lengthened the timeline of their research and evaluated mortality
rates at 30 days and 2 years. 
Methods
The investigators used combinations of Medicare and VA inpatient data from 1998 to
2002 to examine 30-day and 2-year mortality among US-residing black and white elderly
male Medicare or VA enrollees, aged 65 and older, who were hospitalized with a
principal diagnosis of AMI; stroke, hip fracture, CHF, GI bleed or pneumonia. 
Results
• Black male patients made up 8.5% of the 3,656,951 Medicare hospitalizations between 1998
and 2002 and 17.8% of the 155,529 VA hospitalizations in the same time period.
• Patient characteristics were similar in the VA and Medicare research samples. Compared to
white patients, black patients tended to be younger and live in zip codes with lower average
educational attainment and lower median household income. In terms of health, black
patients had more co-morbid conditions on average, with a higher prevalence of conditions
such as hypertension and diabetes. 
• Among Medicare patients, after adjustments for differences in co-morbid conditions,
socioeconomic variables, and hospital site, blacks had significantly lower 30-day mortality
than whites for all of the conditions except AMI. Black VA patients had better 30-day adjusted
mortality outcomes than their white counterparts for all six conditions. 
• At 30 days after admission for
pneumonia, black VA and Medicare
hospitalized patients had better
mortality outcomes than similarly-
hospitalized white patients. 
• At 2 years after admission for
pneumonia, relative mortality
outcomes for blacks in both
settings got worse, but not to the
same degree. At 2 years, VA-
hospitalized black and white
pneumonia patients fared almost
equally.  But among Medicare
patients, white patients had better
mortality outcomes than black
patients.
• At 30 days after admission,
mortality rates for black patients
hospitalized for CHF in VA and
Medicare hospitals were relatively
better than those of similarly-
hospitalized white patients. 
• At 2 years after admission,
mortality outcomes for blacks in
both settings remained better than
those of similarly-hospitalized
white patients. 
At 30 days after
admission for five of
the six conditions,
racial patterns in
mortality outcomes
were similar in VA and
non-VA hospital
settings, with black
patients having a
survival advantage.  
Figure 1: Differences in adjusted percentage mortality rates at 30 days and 2 years
for blacks compared to whites among VA and Medicare patients hospitalized for
pneumonia from 1998-2002. 
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Each point shows the mortality difference
between black and white patients treated in
Medicare (blue diamond) hospitals and
VA (grey square) hospitals
Because these points are above the 
horizontal line, we see that that whites 
do better than blacks after 2 years.
The slope of the lines shows how differences among
black and white patients change over time. Here the
upward slope shows that the black mortality advantage
seen at 30 days goes away by 2 years for VA patients.
For Medicare patients the change is even more drastic, 
with whites doing signifcatly better than blacks at 2 years.
Because these points are below
the horizontal line, we see that that 
blacks do better than whites 30 
days after hospitalization.
Medicare VA
Pneumonia
All points represent statistically significant (p <.5) racial differences in 
outcomes except 2-year mortality for pneumonia among VA patients.
Figure 2: Differences in adjusted percentage mortality rates at 30 days and 2 years
for blacks compared to whites among VA and Medicare patients hospitalized for
CHF from 1998-2002. 
All points represent statistically significant (p <.5) racial differences 
in outcomes.
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• For patients hospitalized with GI bleed, hip fracture, stroke or AMI, at 30 days after
admission, the relative differences in mortality for white and black patients generally favored
black patients and were similar across Medicare and VA hospitalized patients. After 2 years,
among Medicare patients, the relative differences in mortality between black and white
patients reversed, with a comparatively higher percentage of black patients dying after being
hospitalized for any of these conditions. 
• Among VA patients, the 2-year trends were less consistent. The relative advantage in short-
term mortality outcomes for black patients hospitalized for one of the four conditions
remained for AMI. It decreased slightly for GI bleed and disappeared for hip fracture and
stroke, with white VA hospitalized patients having better mortality outcomes after two years.
Implications
Better 30-day relative mortality rates for black patients compared to white patients exist in VA
and non-VA hospitals and remain unexplained at this time. However, increases in comparative
mortality rates for black patients subsequent to the initial 30 days after discharge from both
hospital settings suggest that factors unrelated to hospital care, such as social support, quality of
ambulatory care, or access to prescription drugs, play important roles in longer term mortality
rates. Medical system efforts to reduce racial disparities may need to focus on post-hospital care
and environmental factors. 
The integrated health care delivery system of the VA may attenuate racial disparities in health
by mitigating the environmental factors that contribute to mortality for up to two years after
hospitalization.
Among Medicare
patients, relative to
the mortality
outcomes for whites,
mortality outcomes
for blacks
deteriorated over
time until black
Medicare patients
had worse 2-year
mortality rates for
all conditions except
CHF. 
In contrast, among
VA patients, the
relative decline in
mortality outcomes
for blacks was less
marked and
statistically
significant only for
hip fracture and
stroke. 
Figure 3: Racial differences in adjusted percentage mortality rates at 30 days and 2
years for blacks compared to whites among VA and Medicare patients hospitalized
for GI bleed, hip fracture, stroke and AMI from 1998-2002. 
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All of the points represent statistically significant (p <.5) racial differences in outcomes except 30-day AMI mortality among Medicare
patients and 2-year mortality for GI bleed and hip fracture among VA patients.
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